Literature DB >> 12646010

Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Pierre-Louis Toutain1.   

Abstract

Pharmacokinetic (PK)/pharmacodynamic (PD) modeling is a scientific tool to help developers select a rational dosage regimen for confirmatory clinical testing. This article describes some of the limitations associated with traditional dose-titration designs (parallel and crossover designs) for determining an appropriate dosage regimen. It also explains how a PK/PD model integrates the PK model (describing the relationship between dose, systemic drug concentrations, and time) with the PD model (describing the relationship between systemic drug concentration and the effect vs time profile) and a statistical model (particularly, the intra- and interindividual variability of PK and/or PD origin). Of equal importance is the utility of these models for promoting rational drug selection on the basis of effectiveness and selectivity. PK/PD modeling can be executed using various approaches, such as direct versus indirect response models and parametric versus nonparametric models. PK/PD concepts can be applied to individual dose optimization. Examples of the application of PK/PD approaches in veterinary drug development are provided, with particular emphasis given to nonsteroidal anti-inflammatory drugs. The limits of PK/PD approaches include the development of appropriate models, the validity of surrogate endpoints, and the acceptance of these models in a regulatory environment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12646010      PMCID: PMC2751327          DOI: 10.1208/ps040438

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  62 in total

1.  Role of dosage regimen in controlling indirect pharmacodynamic responses.

Authors:  J V Gobburu; W J Jusko
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Antibiotic efficacy in vivo predicted by in vitro activity.

Authors:  H Mattie
Journal:  Int J Antimicrob Agents       Date:  2000-03       Impact factor: 5.283

Review 3.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 4.  Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.

Authors:  W A Colburn
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

Review 5.  Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Authors:  H Derendorf; L J Lesko; P Chaikin; W A Colburn; P Lee; R Miller; R Powell; G Rhodes; D Stanski; J Venitz
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

6.  New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.

Authors:  P L Toutain; H P Lefebvre; V Laroute
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

7.  Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.

Authors:  P L Toutain; H P Lefebvre; J N King
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

8.  Dose titration of an injectable formulation of lufenuron in cats experimentally infested with fleas.

Authors:  B L Blagburn; J L Vaughan; J M Butler; S C Parks
Journal:  Am J Vet Res       Date:  1999-12       Impact factor: 1.156

9.  Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000).

Authors:  K M Rassnick; D M Ruslander; S M Cotter; R Al-Sarraf; D S Bruyette; R M Gamblin; K A Meleo; A S Moore
Journal:  J Am Vet Med Assoc       Date:  2001-05-01       Impact factor: 1.936

Review 10.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
View more
  20 in total

1.  Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat.

Authors:  Jerome M Giraudel; Armelle Diquelou; Valerie Laroute; Peter Lees; Pierre-Louis Toutain
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.

Authors:  Holger Dette; Andrey Pepelyshev; Weng Kee Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-22       Impact factor: 2.745

5.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.

Authors:  Santosh Kumar Puttrevu; Rachumallu Ramakrishna; Manisha Bhateria; Moon Jain; Kashif Hanif; Rabi Sankar Bhatta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

6.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study.

Authors:  Christian Höcht; Carla Di Verniero; Javier A W Opezzo; Guillermo F Bramuglia; Carlos A Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-30       Impact factor: 3.000

7.  Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.

Authors:  Omar Vesga; Maria Agudelo; Beatriz E Salazar; Carlos A Rodriguez; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.

Authors:  Yan Wang; Bo Lin
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

9.  Enrofloxacin Dose Optimization for the Treatment of Colibacillosis in Broiler Chickens Using a Drinking Behaviour Pharmacokinetic Model.

Authors:  Robin Temmerman; Ludovic Pelligand; Wim Schelstraete; Gunther Antonissen; An Garmyn; Mathias Devreese
Journal:  Antibiotics (Basel)       Date:  2021-05-19

10.  Synovial distribution of "systemically" administered acetylsalicylic acid in the isolated perfused equine distal limb.

Authors:  Maren Friebe; Stephan Schumacher; Jessica Stahl; Manfred Kietzmann
Journal:  BMC Vet Res       Date:  2013-03-26       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.